JPRN-UMIN000015602
Recruiting
N/A
Evaluation of the clinical efficacy and safety of fluticasone propionate/ formoterol fumarate combination (FFC) for the treatment of bronchial asthma-with and without use of an inhalation device - Evaluation of the clinical efficacy and safety of fluticasone propionate/ formoterol fumarate combination (FFC) for the treatment of bronchial asthma-with and without use of an inhalation device
Kinki university Department of respiratory medicine and allergology0 sites50 target enrollmentNovember 4, 2014
ConditionsBronchial Asthma
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Bronchial Asthma
- Sponsor
- Kinki university Department of respiratory medicine and allergology
- Enrollment
- 50
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Patients with any serious cardiac, hepatic, renal, hematological disorder, or any other serious complication 2\) Patients who have coexisting malignant tumor or a history of malignant tumor 3\) Patients who have history of smoking within the past 1 year 4\) Patients who are pregnant, lactating, possibly pregnant, or those who desire to become pregnant during their participation in the study 5\) Others deemed unsuitable by the investigator
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, Not Recruiting
Phase 1
A comparison of a single-pill combination of perindopril/indapamide/amlodipine/bisoprolol with perindopril,indapamide and amlodipine in patients with essential hypertension whose blood pressure remains high on perindopril, indapamide and amlodipine treatment.HypertensionMedDRA version: 20.0Level: PTClassification code 10020772Term: HypertensionSystem Organ Class: 10047065 - Vascular disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2020-004891-16-LVInstitut de Recherches Internationales Servier968
Active, Not Recruiting
Phase 1
A comparison of a single-pill combination of perindopril/indapamide/amlodipine/bisoprolol with perindopril,indapamide and amlodipine in patients with essential hypertension whose blood pressure remains high on perindopril, indapamide and amlodipine treatment.HypertensionMedDRA version: 20.0Level: PTClassification code 10020772Term: HypertensionSystem Organ Class: 10047065 - Vascular disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2020-004891-16-CZInstitut de Recherches Internationales Servier968
Active, Not Recruiting
Phase 1
A comparison of a single-pill combination of perindopril/indapamide/amlodipine/bisoprolol with perindopril,indapamide and amlodipine in patients with essential hypertension whose blood pressure remains high on perindopril, indapamide and amlodipine treatment.HypertensionMedDRA version: 20.0Level: PTClassification code 10020772Term: HypertensionSystem Organ Class: 10047065 - Vascular disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2020-004891-16-PLInstitut de Recherches Internationales Servier968
Active, Not Recruiting
Phase 1
A comparison of a single-pill combination of perindopril/indapamide/amlodipine/bisoprolol with perindopril,indapamide and amlodipine in patients with essential hypertension whose blood pressure remains high on perindopril, indapamide and amlodipine treatment.HypertensionMedDRA version: 20.0Level: PTClassification code 10020772Term: HypertensionSystem Organ Class: 10047065 - Vascular disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2020-004891-16-HUInstitut de Recherches Internationales Servier968
Active, Not Recruiting
Phase 1
A comparison of a single-pill combination of perindopril/indapamide/amlodipine/bisoprolol with perindopril, indapamide and amlodipine in patients with essential hypertension whoseblood pressure remains high on perindopril, indapamide and amlodipine treatment.HypertensionMedDRA version: 20.0Level: PTClassification code 10020772Term: HypertensionSystem Organ Class: 10047065 - Vascular disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2020-004891-16-ITINSTITUT DE RECHERCHES INTERNATIONALES SERVIER968